CancerWorld shared a post on LinkedIn:
“What happens when one of oncology’s most elusive targets finally becomes treatable?
For decades, RAS was considered ‘undruggable‘. The Phase III RASolute 302 trial is now challenging that belief—and reshaping the future of metastatic pancreatic cancer.
In this exclusive interview, Dr. Eileen O’Reilly explains why daraxonrasib represents more than a breakthrough drug. It signals a new era of precision oncology for one of medicine’s most challenging diseases.
Other posts about CancerWorld on OncoDaily.